The Oncologist, discusses a series of articles on pegylated liposomal doxorubicin (PLD) and its relation to ovarian cancer and other cancers.

Dr. Bruce A. Chabner, Editor-in-Chief of The Oncologist, discusses a series of articles on pegylated liposomal doxorubicin (PLD) and its relation to ovarian cancer and other cancers.

Ovarian cancer is the second most common gynecological cancer in women and is often not diagnosed until it's at stage III. Most patients require surgery, along with chemotherapy, but in a majority of patients, the cancer still recurs. Additional preventative maintenance with pegylated liposomal doxorubicin (PLD) can be prescribed long-term to try to avert such recurrence. However, critical side effects are emerging, providing a significant opportunity for researchers to examine the safety versus the efficacy of PLD. Specifically, chronic kidney disease (CKD), as well as oral squamous cell carcinoma (SCC) have been noted in patients who have received long-term treatment with PLD.   Go to the special series on PLD >>>   This special series includes two research articles and three letters to the Editor, all published in the December issue of The Oncologist.

http://m.theoncologist.alphamedpress.org/site/misc/PLD_articles.xhtml?utm_source=iContact&utm_medium=email&utm_campaign=Newsletter@The%2520Oncologist.com&utm_content=December+Newsletter+In+Production